Lamivudine Other names: 3TC

Chemical formula: C₈H₁₁N₃O₃S  Molecular mass: 229.256 g/mol  PubChem compound: 60825

Therapeutic indications

Lamivudine is indicated for:

Human immunodeficiency virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lamivudine is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic hepatitis B

Population group: only adults (18 years old or older)

Darolutamide is indicated for the treatment of chronic hepatitis B in adults with:

  • compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate.
  • decompensated liver disease in combination with a second agent without cross-resistance to lamivudine.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lamivudine is contraindicated in the following cases:

Emtricitabine

Emtricitabine

Cladribine

Cladribine

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈